Back to search results

Registry for Ventricular Tachycardia Catheter Ablation

This is an observational study, or registry, collecting information on patients who undergo catheter ablation for ventricular tachycardia (VT) or premature ventricular contractions (PVCs). Catheter ablation is a procedure that uses energy to destroy small areas of heart tissue that cause irregular heartbeats. The study aims to gather data from many centers worldwide to better understand how well this procedure works and its benefits. The main goal is to track if your ventricular tachycardia returns after the procedure, which will be checked for up to 10 years. Anyone undergoing catheter ablation for VT or PVCs can participate.

Study design
This is an observational registry that plans to enroll up to 10,000 participants across multiple centers.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 10 years to assess for ventricular tachycardia recurrence.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04520347

IVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry

Enrolling by Invitation
Not specifiedAll AgesObservational
University of California, Los Angeles
~10,000 participants
Updated 2025-12-15 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 41 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Ventricular tachycardia (VT) recurrence
Measured over From date of procedure assessed by shock, Anti-Tachycardia Pacing, or repeat procedure, up to 10 years.

Conditions

Ventricular Arrhythmia
Ventricular Tachycardia
Premature Ventricular Contraction (PVC)
Cardiomyopathy

Explore related trials

Ventricular premature complexVentricular Tachycardia

NCT04520347

Where you'd take part

This study runs at 41 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Banner Health, University of Arizona Medical Center

    Phoenix, Arizonano site contact published

  • Beth Israel Deaconess Medical Center

    Boston, Massachusettsno site contact published

  • Boston Children's Hospital

    Boston, Massachusettsno site contact published

  • Brigham and Women's Hospital

    Boston, Massachusettsno site contact published

  • Cedars-Sinai Medical Center

    Los Angeles, Californiano site contact published

  • Children's Hospital of Pennsylvania

    Philadelphia, Pennsylvaniano site contact published

  • Cleveland Clinic Foundation

    Cleveland, Ohiono site contact published

  • Columbia University Irving Medical Center

    New York, New Yorkno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jason Bradfield, MD · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles
  • Kalyanam Shivkumar, MD, PhD · STUDY_CHAIR · University of California, Los Angeles
  • Paolo Della Bella, MD · STUDY_CHAIR · San Raffaele Hospital, Italy
  • Francis Marchlinski, MD, FACC, FAHA, FHRS · STUDY_CHAIR · University of Pennsylvania Health System
  • Andrea Natale, MD, FACC, FHRS, FESC · STUDY_CHAIR · Texas Cardiac Arrhythmia Institute at St. David's Medical Center
  • William G Stevenson, MD · STUDY_CHAIR · Vanderbilt Heart and Vascular Institute

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Ventricular tachycardia (VT) recurrenceFrom date of procedure assessed by shock, Anti-Tachycardia Pacing, or repeat procedure, up to 10 years.

    Freedom from ventricular tachycardia episodes requiring ICD Intervention (shock or Anti-Tachycardia Pacing) or repeat procedure.